Monday, 24 Feb 2020

You are here

Upadacitinib Effective in Ankylosing Spondylitis

Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.

The SELECT-AXIS 1, enrolled adults with active ankylosing spondylitis patients who were biologics naive and were randomized to receive upadacitinib 15 mg once daily or placebo for the 14-weeks. The primary endpoint was the composite outcome measure of the Assessment of SpondyloArthritis international Society 40 (ASAS40) response at week 14.

A total of 187 patients were treated.  UPAD had significantly more patients achieving an ASAS40 response at week 14 (52% vs 26%; p=0·0003).

Common adverse events with upadacitinib included increased creatine phosphokinase levels in 9% (2% with PBO). There were no serious infections, herpes zoster, malignancy, venous thromboembolic events, or deaths reported.

This is one of th first trials showing that JAK inhibition (with upadacitinib) is efficacious in active ankylosing spondylitis. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

No Cancer Increase in Psoriatic Arthritis or with Biologics in Psoriasis

JAMA Dermatology reports that psoriasis is associated with a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas.

A systematic review and meta-analysis of 112 studies including more than 2 million patients, also shows no increase in when psoriasis is treated with biologic agents, nor was psoriatic arthritis associated with an increased risk of cancer.   

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.